Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Dietary intake of advanced glycation endproducts and risk of hepatobiliary cancers: A multinational cohort study

  • Ana Lucia Mayén
  • , Elom K. Aglago
  • , Viktoria Knaze
  • , Reynalda Cordova
  • , Casper G. Schalkwijk
  • , Karl Heinz Wagner
  • , Krasimira Aleksandrova
  • , Veronika Fedirko
  • , Pekka Keski-Rahkonen
  • , Michael F. Leitzmann
  • , Verena Katzke
  • , Bernard Srour
  • , Matthias B. Schulze
  • , Giovanna Masala
  • , Vittorio Krogh
  • , Salvatore Panico
  • , Rosario Tumino
  • , Bas Bueno-de-Mesquita
  • , Magritt Brustad
  • , Antonio Agudo
  • María Dolores Chirlaque López, Pilar Amiano, Bodil Ohlsson, Stina Ramne, Dagfinn Aune, Elisabete Weiderpass, Mazda Jenab, Heinz Freisling

Veröffentlichungen: Beitrag in FachzeitschriftArtikelPeer Reviewed

OriginalspracheEnglisch
Seiten (von - bis)854-864
Seitenumfang11
FachzeitschriftInternational Journal of Cancer
Jahrgang149
Ausgabenummer4
DOIs
PublikationsstatusVeröffentlicht - 15 Aug. 2021

Fördermittel

The authors would like to thank the EPIC study participants and staff for their valuable contribution to this research. The authors would also like to especially thank Mr. Bertrand Hemon and Ms. Corinne Casagrande for preparing the EPIC databases. This study was funded by the Fondation de France (FDF, grant no. 00081166, Heinz Freisling and Reynalda Cordova and FDF grant no. 00089811, Ana\u2010Lucia May\u00E9n). Mazda Jenab and Elom K. Aglago acknowledge funding by the Wereld Kanker Onderzoek Fonds (WKOF), as part of the World Cancer Research Fund (WCRF) International grant program (WCRF 2015\u20101391, P.I. Dr. Mazda Jenab, International Agency for Research on Cancer). The coordination of EPIC is financially supported by the European Commission (DG\u2010SANCO); and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer; Institut Gustave Roussy; Mutuelle G\u00E9n\u00E9rale de l'Education Nationale; and Institut National de la Sant\u00E9 et de la Recherche M\u00E9dicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ) and Federal Ministry of Education and Research (BMBF) (Germany); Italian Association for Research on Cancer (AIRC); National Research Council; and Associazione Iblea per la Ricerca Epidemiologica (AIRE\u2010ONLUS) Ragusa, Associazione Volontari Italiani Sangu (AVIS) Ragusa, Sicilian Government (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS); Netherlands Cancer Registry (NKR); LK Research Funds; Dutch Prevention Funds; Dutch ZON (Zorg Onderzoek Nederland); World Cancer Research Fund (WCRF); and Statistics Netherlands (the Netherlands); Health Research Fund (FIS); Regional Governments of Andaluc\u00EDa, Asturias, Basque Country, Murcia (No. 6236) and Navarra; and the Centro de Investigaci\u00F3n Biom\u00E9dica en Red en Epidemiolog\u00EDa y Salud P\u00FAblica and Instituto de Salud Carlos II (ISCIII RETIC) (RD06/0020) (Spain); Health Research Fund (FIS)\u2014Instituto de Salud Carlos III (ISCIII), Regional Governments of Andaluc\u00EDa, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology\u2014ICO (Spain); Swedish Cancer Society; Swedish Scientific Council; and Regional Government of Sk\u00E5ne and V\u00E4sterbotten (Sweden); Cancer Research UK; Medical Research Council; Stroke Association; British Heart Foundation; Department of Health; Food Standards Agency; and the Wellcome Trust (UK). Cancer Research UK (14136 to EPIC\u2010Norfolk; C570/A16491 and C8221/A19170 and C8221/A29017 to EPIC\u2010Oxford), Medical Research Council (1000143 to EPIC\u2010Norfolk, MR/M012190/1 to EPIC\u2010Oxford) (United Kingdom). The EPIC\u2010Norfolk study (DOI 10.22025/2019.10.105.00004 ) has received funding from the Medical Research Council (MR/N003284/1 and MC\u2010UU_12015/1) and Cancer Research UK (C864/A14136). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article. The authors would like to thank the EPIC study participants and staff for their valuable contribution to this research. The authors would also like to especially thank Mr. Bertrand Hemon and Ms. Corinne Casagrande for preparing the EPIC databases. This study was funded by the Fondation de France (FDF, grant no. 00081166, Heinz Freisling and Reynalda Cordova and FDF grant no. 00089811, Ana-Lucia May\u00E9n). Mazda Jenab and Elom K. Aglago acknowledge funding by the Wereld Kanker Onderzoek Fonds (WKOF), as part of the World Cancer Research Fund (WCRF) International grant program (WCRF 2015-1391, P.I. Dr. Mazda Jenab, International Agency for Research on Cancer). The coordination of EPIC is financially supported by the European Commission (DG-SANCO); and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer; Institut Gustave Roussy; Mutuelle G\u00E9n\u00E9rale de l'Education Nationale; and Institut National de la Sant\u00E9 et de la Recherche M\u00E9dicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ) and Federal Ministry of Education and Research (BMBF) (Germany); Italian Association for Research on Cancer (AIRC); National Research Council; and Associazione Iblea per la Ricerca Epidemiologica (AIRE-ONLUS) Ragusa, Associazione Volontari Italiani Sangu (AVIS) Ragusa, Sicilian Government (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS); Netherlands Cancer Registry (NKR); LK Research Funds; Dutch Prevention Funds; Dutch ZON (Zorg Onderzoek Nederland); World Cancer Research Fund (WCRF); and Statistics Netherlands (the Netherlands); Health Research Fund (FIS); Regional Governments of Andaluc\u00EDa, Asturias, Basque Country, Murcia (No. 6236) and Navarra; and the Centro de Investigaci\u00F3n Biom\u00E9dica en Red en Epidemiolog\u00EDa y Salud P\u00FAblica and Instituto de Salud Carlos II (ISCIII RETIC) (RD06/0020) (Spain); Health Research Fund (FIS)\u2014Instituto de Salud Carlos III (ISCIII), Regional Governments of Andaluc\u00EDa, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology\u2014ICO (Spain); Swedish Cancer Society; Swedish Scientific Council; and Regional Government of Sk\u00E5ne and V\u00E4sterbotten (Sweden); Cancer Research UK; Medical Research Council; Stroke Association; British Heart Foundation; Department of Health; Food Standards Agency; and the Wellcome Trust (UK). Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 and C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). The EPIC-Norfolk study (DOI 10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1 and MC-UU_12015/1) and Cancer Research UK (C864/A14136). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

ÖFOS 2012

  • 303009 Ernährungswissenschaften

Fingerprint

Untersuchen Sie die Forschungsthemen von „Dietary intake of advanced glycation endproducts and risk of hepatobiliary cancers: A multinational cohort study“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitationsweisen